小猪视频app

Form: 10-Q

Quarterly report pursuant to Section 13 or 15(d)

November 15, 1999

STATEMENT RE: COMPUTATION OF EARNINGS PER SHARE

Published on November 15, 1999




EXHIBIT 11

CYTOCLONAL PHARMACEUTICS INC.


COMPUTATION OF NET (LOSS) PER COMMON SHARE
(unaudited)




THREE MONTHS NINE MONTHS
ENDED SEPTEMBER 30, ENDED SEPTEMBER 30,
1999 1998 1999 1998
------------ ------------ ------------ ------------

Net (loss) ($ 1,012,000) ($ 976,000) ($ 2,924,000) ($ 1,935,000)

Add cumulative preferred dividend (46,000) (48,000) (137,000) (143,000)
------------ ------------ ------------ ------------

NET (LOSS) USED FOR COMPUTATION ($ 1,058,000) ($ 1,024,000) ($ 3,061,000) ($ 2,078,000)

Weighted average number of common
shares outstanding - basic and
diluted 10,361,000 10,172,000 10,318,000 9,585,000
------------ ------------ ------------ ------------

Net (loss) per common share -
basic and diluted ($ 0.10) ($ 0.10) ($ 0.30) ($ 0.22)